Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-89
SponsorNational University of Singapore
About this trial
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.
Eligibility criteria
Qualifiers
Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.
BMI of ≥ 30 kg/m2 (obesity); OR
BMI of ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
Disqualifiers
Pregnancy or lactation.
Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.
Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.
On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.
Trial design
Treatments tested in this trial
- Not applicable. This is an observational study.
Treatment groups
440 Participants
are divided into 1 treatment groupLocations
2National University of Singapore119077, Singapore Singapore
NOVI Health (T3 Health PTE LTD)068914, Singapore Singapore
Sponsors and collaborators
National University of Singapore
Lead sponsor
T3 Health PTE LTD
Collaborator
Source ClinicalTrials.gov